Rheumatology News

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

The FDA has granted rare pediatric disease designation to Descartes-08, an autologous mRNA cell therapy, for the treatment of juvenile dermatomyositis, Cartesian Therapeutics announced in a press release.

One important investment vehicle to understand when working toward slow and steady growth is the index fund.

Upadacitinib shows superior clinical, radiographic and patient-reported outcomes in RA, and has a more favorable risk-benefit profile, compared with methotrexate over 5 years, according to data published in Arthritis Research & Therapy.

A letter from the AMA's executive vice president called for CMS to be “fully transparent” on the impact that payment cuts in the 2025 Physician Fee Schedule will have on patients and physicians.

Biosimilar medications — drugs developed to be very similar, but not identical, to an FDA-approved biologic — were intended to play a vital role in increasing affordable options for patients struggling with a range of chronic conditions.

Chimeric antigen receptor T-cell therapy and precision medicine will highlight the agenda at the 40th annual Congress of Clinical Rheumatology West, set for Sept. 26 to Sept. 29 in San Diego, California.

Practicing shared decision-making increases overall trust in health care providers among patients with systemic lupus erythematosus, according to data published in Arthritis Care & Research.

The COVID-19 pandemic had a great impact on the health care system and the well-being of health care professionals, the effects of which are still felt today.

COVID-19 does not increase patients’ risk for developing myalgic encephalomyelitis/chronic fatigue syndrome during the 1-year period post infection, according to a registry study published in JAMA Network Open.